JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Search

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

47.59 -0.81

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

47.59

Max

48.2

Galvenie mērījumi
By Trading Economics
Ienākumi	6.6M -39M
Pārdošana	19M 212M
P/E Sektora vidējais	48.435 67.147
EPS	0.882
Peļņas marža	-18.221
Darbinieki	778
EBITDA	127M 90M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+32.02% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-59M 2.8B
Iepriekšējā atvēršanas cena	48.4
Iepriekšējā slēgšanas cena	47.59

Ziņu noskaņojums

By Acuity

60%

40%

292 / 347 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

31.35 / 32.36 Atbalsts un pretestība

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. maijs 23:47 UTC

Peļņas

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

2026. g. 3. maijs 22:35 UTC

Peļņas

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

2026. g. 3. maijs 23:39 UTC

Tirgus saruna

Gold Edge Higher Amid Signs of Resilience -- Market Talk

2026. g. 3. maijs 23:34 UTC

Tirgus saruna

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

2026. g. 3. maijs 23:32 UTC

Peļņas

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

2026. g. 3. maijs 23:30 UTC

Tirgus saruna

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

2026. g. 3. maijs 23:20 UTC

Tirgus saruna

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

2026. g. 3. maijs 23:16 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

2026. g. 3. maijs 22:57 UTC

Iegādes, apvienošanās, pārņemšana

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

2026. g. 3. maijs 22:45 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. maijs 22:45 UTC

Tirgus saruna

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

2026. g. 3. maijs 22:20 UTC

Peļņas

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

2026. g. 3. maijs 22:08 UTC

Peļņas

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

2026. g. 3. maijs 22:05 UTC

Peļņas

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

2026. g. 3. maijs 22:04 UTC

Peļņas

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

2026. g. 3. maijs 22:03 UTC

Peļņas

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

2026. g. 3. maijs 22:03 UTC

Peļņas

NAB 1H Cash Return on Equity 8.5%>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H Cash Earnings A$2.64B>NAB.AU

2026. g. 3. maijs 22:02 UTC

Peļņas

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

2026. g. 3. maijs 22:01 UTC

Peļņas

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

2026. g. 3. maijs 15:06 UTC

Peļņas

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

32.02% augšup

Prognoze 12 mēnešiem

Vidējais 63.17 USD 32.02%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

292 / 347 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Citi krājumi no sektora

JNJ

Johnson and Johnson

227.46

UNH

UnitedHealth Group Inc

369.01

TMO

Thermo Fisher Scientific Inc

469.28

ISRG

Intuitive Surgical Inc

457.59

ABT

Abbott Laboratories

89.51

Live chat